北京科拓恒通生物技术股份有限公司 2021 年年度报告全文 北京科拓恒通生物技术股份有限公司 2021 年年度报告 2022-016 2022 年 04 月 1 北京科拓恒通生物技术股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人刘晓军、主管会计工作负责人余子英及会计机构负责人(会计主 管人员)余子英声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及的未来计划等前瞻性描述不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。敬请广大投资者理性投资，注意风险。 公司可能面临的风险详见本报告"第三节 管理层讨论与分析"之"十一、公 司未来发展的展望"之"（二）公司面临的风险和应对措施"，敬请投资者关注相 关内容。 公司经本次董事会审议通过的利润分配预案为：以截至 2021 年 12 月 31 日 的总股本 ...

Financial Performance - The company's revenue for Q3 2021 was ¥100,988,785.61, a decrease of 2.64% compared to the same period last year, while year-to-date revenue increased by 10.01% to ¥268,295,524.00[3] - Net profit attributable to shareholders for Q3 2021 was ¥40,239,800.67, an increase of 18.52% year-on-year, with a year-to-date net profit of ¥84,830,878.68, up 16.95%[3] - Total revenue for Q3 2021 reached ¥268,295,524, an increase of 10.5% compared to ¥243,871,977 in Q3 2020[23] - Operating profit for Q3 2021 was ¥94,074,340, up from ¥89,505,458 in the same period last year, reflecting a growth of 6.0%[23] - Net profit for Q3 2021 was ¥84,830,878, representing a 16.9% increase from ¥72,534,281 in Q3 2020[24] Earnings and Shares - The basic earnings per share for Q3 2021 was ¥0.27, reflecting an increase of 8.00% compared to the same period last year[3] - Basic earnings per share for Q3 2021 were 0.57, down from 0.61 in the previous period[25] - The total number of shares outstanding as of the report date was 148,531,845, reflecting an 80.00% increase from the previous year-end due to capital reserve conversion[4] - The total number of common shareholders at the end of the reporting period is 10,338[10] - The largest shareholder, Sun Tiansong, holds 30.24% of shares, totaling 44,918,642 shares[10] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥988,612,337.01, a decrease of 1.06% from the end of the previous year[3] - Total current assets decreased to ¥711,653,853.04 from ¥767,208,962.30, a decline of 7.3%[20] - Total non-current assets increased to ¥276,958,483.97 from ¥232,036,849.77, a growth of 19.4%[20] - Total liabilities decreased to ¥49,347,953.85 from ¥66,658,603.19, a reduction of 26.0%[21] - The company's cash and cash equivalents were ¥123,118,317.79, down from ¥202,292,031.68, a decline of 39.1%[20] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥61,530,897.19, an increase of 9.11%[3] - Cash inflow from operating activities totaled ¥334,346,992.91, an increase from ¥274,217,537.37 in the previous period, representing a growth of approximately 22%[26] - Net cash flow from operating activities was ¥61,530,897.19, compared to ¥56,393,678.63 in the previous period, indicating an increase of about 9%[26] - Cash inflow from investment activities was ¥1,093,542,173.35, significantly higher than ¥251,990,382.78 in the previous period[27] - The company reported a total cash outflow from financing activities of ¥79,596,745.85, compared to ¥9,070,000.00 in the previous period[27] Research and Development - Research and development expenses for the year-to-date period rose by 66.40% to ¥21,408,593.71, driven by increased R&D projects[8] - Research and development expenses for Q3 2021 were ¥21,408,593.71, compared to ¥12,866,028.45 in Q3 2020, an increase of 66.5%[23] Shareholder Information - The company has 61,887,692 restricted shares at the beginning of the period, with 15,960,432 shares released during the period, resulting in 95,437,413 restricted shares at the end[14] - The company adjusted the number of restricted stock grants from 820,000 to 1,476,000 shares, with the grant price reduced from 30.00 CNY to 16.11 CNY[15] - The company's registered capital increased from 82,517,692.00 CNY to 148,531,845.00 CNY after the equity distribution[16] - A total of 23,291,338 shares were released from restrictions on July 27, 2021, including 15,960,432 shares available for circulation[17] - The top ten shareholders hold significant stakes, with the second-largest shareholder holding 12.10%[10] Accounting and Reporting - The report for the third quarter was not audited, indicating preliminary figures[33] - The company is implementing new leasing standards affecting the financial statements, indicating a strategic adjustment in accounting practices[28] - The company has implemented new leasing standards effective from January 1, 2021, impacting financial reporting[33]

北京科拓恒通生物技术股份有限公司 2021 年半年度报告全文 北京科拓恒通生物技术股份有限公司 2021 年半年度报告 2021-062 2021 年 08 月 1 北京科拓恒通生物技术股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人刘晓军、主管会计工作负责人余子英及会计机构负责人(会计主 管人员)余子英声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及的未来计划等前瞻性描述不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。敬请广大投资者理性投资，注意风险。公司可能面临 的风险详见本报告"第三节 管理层讨论与分析"之"十、公司面临的风险和应对 措施"，敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 错误!未定义书签。 ...

Financial Performance - The company's revenue for Q1 2021 was ¥80,716,575.97, representing a 35.97% increase compared to ¥59,362,530.32 in the same period last year[7]. - Net profit attributable to shareholders was ¥21,558,322.68, up 43.07% from ¥15,068,263.54 year-on-year[7]. - Basic and diluted earnings per share increased by 8.33% to ¥0.26 from ¥0.24 in the same period last year[7]. - Total operating revenue for Q1 2021 reached CNY 80,716,575.97, compared to CNY 59,362,530.32 in the previous period, indicating a significant increase[44]. - The net profit for the first quarter reached CNY 21,558,322.68, compared to CNY 15,068,263.54 in the same period last year, representing a growth of approximately 43.3%[46]. - The operating profit for the first quarter was CNY 25,935,302.59, compared to CNY 20,359,440.53 in the previous year, reflecting a growth of approximately 27.5%[46]. - The total profit for the first quarter was CNY 25,835,238.25, compared to CNY 18,102,505.30 in the previous year, representing an increase of approximately 42.5%[46]. Cash Flow - The net cash flow from operating activities was ¥19,110,813.82, a significant improvement from a negative cash flow of ¥1,481,423.99 in the previous year, marking a 1,390.03% increase[7]. - Cash flow from operating activities was CNY 19,110,813.82, a significant increase of 1390.03% compared to a negative cash flow of CNY -1,481,423.99 in the same period last year[20]. - The cash flow from operating activities for Q1 2021 was ¥122,267,392.49, compared to ¥60,254,713.07 in the previous period, indicating a substantial increase[53]. - The cash inflow from the recovery of investments for the parent company was ¥385,324,608.59, a substantial increase from ¥26,050,060.28 in the same period last year[58]. - The company reported a total operating cash inflow of ¥125,004,472.30, which is an increase of approximately 97% from ¥63,258,584.97 in the previous year[54]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,016,465,616.03, a 1.72% increase from ¥999,245,812.07 at the end of the previous year[7]. - The total assets as of March 31, 2021, amounted to CNY 1,016,465,616.03, up from CNY 999,245,812.07 at the end of 2020[39]. - The total liabilities decreased to CNY 61,412,684.47 from CNY 66,658,603.19, showing a decline of approximately 8.5%[38]. - The company’s total liabilities increased from ¥66,658,603.19 to ¥71,479,794.01, reflecting a rise of approximately 7%[62]. - The total current assets were CNY 765,757,693.48, with cash and cash equivalents at CNY 171,936,567.89[64]. Shareholder Information - The company reported a total of 10,006 common shareholders at the end of the reporting period[11]. - The top shareholder, Sun Tiansong, holds 30.24% of the shares, totaling 24,954,801 shares[11]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12]. Research and Development - Research and development expenses rose by 86.36% to CNY 6,362,429.11, driven by increased R&D activities[18]. - Research and development expenses amounted to CNY 6,362,429.11, up from CNY 3,414,045.63, indicating a year-over-year increase of about 86.5%[46]. Government Support - The company received government subsidies amounting to ¥1,208,098.97 during the reporting period[8]. Other Financial Metrics - The total amount of raised funds is CNY 436.18 million, with CNY 2.25 million invested in the current quarter[27]. - The project for producing 30 tons of lactic acid bacteria powder and other products has achieved a completion rate of 100.02%[27]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[30]. - There were no violations of external guarantees during the reporting period[29].

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Section%20I%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) The company's board, supervisory board, and senior management ensure the report's truthfulness and completeness, with no plans for semi-annual profit distribution - The company's board of directors, supervisory board, and senior management ensure the truthfulness, accuracy, and completeness of this semi-annual report and assume legal responsibility. During the reporting period, the company plans no cash dividends, bonus shares, or capital increase from capital reserves[4](index=4&type=chunk)[6](index=6&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=Section%20II%20Company%20Profile%20and%20Key%20Financial%20Indicators) [Company Profile](index=6&type=section&id=I.%20Company%20Profile) Beijing Kairui Hengtong Biotechnology Co., Ltd. (Kairui Bio, stock code 300858) is a Shenzhen Stock Exchange-listed company, with Liu Xiaojun as its legal representative Company Basic Information | Item | Content | | :--- | :--- | | **Stock Abbreviation** | Kairui Bio | | **Stock Code** | 300858 | | **Listing Exchange** | Shenzhen Stock Exchange | | **Full Chinese Name** | Beijing Kairui Hengtong Biotechnology Co., Ltd. | | **Legal Representative** | Liu Xiaojun | [Key Accounting Data and Financial Indicators](index=7&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2020, revenue grew 3.26% to 140.15 million yuan, while net profit attributable to shareholders decreased by 4.33% to 38.58 million yuan Key Financial Indicators for H1 2020 | Indicator | Current Reporting Period | Prior Year Period | Year-on-year Change | | :--- | :--- | :--- | :--- | | Operating Revenue (Million Yuan) | 140.15 | 135.73 | 3.26% | | Net Profit Attributable to Shareholders (Million Yuan) | 38.58 | 40.33 | -4.33% | | Net Profit Excluding Non-recurring Items (Million Yuan) | 37.86 | 35.96 | 5.28% | | Net Cash Flow from Operating Activities (Million Yuan) | 25.88 | 44.31 | -41.58% | | Basic Earnings Per Share (yuan/share) | 0.62 | 0.65 | -4.62% | | Weighted Average Return on Net Assets | 9.21% | 12.34% | -3.13% | | **Indicator** | **End of Current Reporting Period** | **End of Prior Year** | **Year-on-year Change** | | Total Assets (Million Yuan) | 491.60 | 465.97 | 5.50% | | Net Assets Attributable to Shareholders (Million Yuan) | 438.41 | 399.83 | 9.65% | [Non-recurring Gains and Losses and Amounts](index=8&type=section&id=VI.%20Non-recurring%20Gains%20and%20Losses%20and%20Amounts) Total non-recurring gains and losses amounted to 0.72 million yuan, primarily from government subsidies, asset disposal losses, and COVID-19 related donations Non-recurring Gains and Losses Items for H1 2020 | Item | Amount (Million Yuan) | Explanation | | :--- | :--- | :--- | | Non-current asset disposal gains and losses | -0.82 | Losses from clearing fixed assets due to subsidiary Jinhua Yinhe production base relocation | | Government subsidies included in current profit/loss | 3.58 | - | | Other non-operating income and expenses | -2.42 | Primarily donations to Wuhan Leishenshan Hospital and medical staff during the COVID-19 pandemic | | Fair value changes from transactional financial assets, etc. | 0.52 | - | | Less: Income tax impact | 0.14 | - | | **Total** | **0.72** | **--** | [Company Business Overview](index=9&type=section&id=Section%20III%20Company%20Business%20Overview) [Main Businesses During the Reporting Period](index=9&type=section&id=I.%20Main%20Businesses%20During%20the%20Reporting%20Period) The company specializes in R&D, production, and sales of compound food additives, edible probiotics, and animal/plant micro-ecological preparations - The company's main products are categorized into three types: - **Compound Food Additives**: Primarily used in dairy products like yogurt for thickening, emulsifying, and improving taste[27](index=27&type=chunk) - **Edible Probiotic Products**: Includes raw bacterial powders for enterprises and own-brand products for end consumers[28](index=28&type=chunk) - **Animal and Plant Micro-ecological Preparations**: Applied in livestock farming and crop cultivation to regulate flora and improve soil[29](index=29&type=chunk) - The company's performance is primarily driven by the deep integration of its compound food additive business with client terminal products and customer recognition of its edible probiotic business due to effective core strains[36](index=36&type=chunk) [Significant Changes in Major Assets](index=10&type=section&id=II.%20Significant%20Changes%20in%20Major%20Assets) Fixed assets increased by 83.47% due to construction in progress, while accounts receivable decreased by 51.72% and notes receivable surged by 1009.21% due to settlement changes Explanation of Major Asset Changes | Major Asset | Significant Change Explanation | | :--- | :--- | | Fixed Assets | Increased by **83.47%** from the beginning of the year, mainly due to the transfer of construction in progress at subsidiary Jinhua Yinhe to fixed assets | | Accounts Receivable | Decreased by **51.72%** from the beginning of the year, mainly because major client Mengniu Dairy settled some payments with bank acceptance bills due to the COVID-19 pandemic | | Notes Receivable | Increased by **1,009.21%** from the beginning of the year, mainly because major client Mengniu Dairy settled some payments with bank acceptance bills due to the COVID-19 pandemic | [Analysis of Core Competencies](index=11&type=section&id=III.%20Analysis%20of%20Core%20Competencies) The company's core strengths include strong R&D, a stable customer base, robust quality management, and an experienced management team - The company holds **56 invention patents** related to probiotics and one of the largest lactic acid bacteria strain resource libraries in China, with highly influential technical leaders in the industry[38](index=38&type=chunk) - The company has established long-term strategic partnerships with leading domestic dairy and livestock farming enterprises such as Mengniu, Guangming, and Wandashan, ensuring high customer loyalty[40](index=40&type=chunk) - The company has obtained ISO 9001, ISO 22000, and international Halal certifications, demonstrating leading food safety and quality management standards[41](index=41&type=chunk) [Discussion and Analysis of Operations](index=12&type=section&id=Section%20IV%20Discussion%20and%20Analysis%20of%20Operations) [Overview](index=12&type=section&id=I.%20Overview) In H1 2020, total operating revenue was 140.15 million yuan (+3.26%), and net profit attributable to shareholders was 38.58 million yuan (-4.33%), with varied performance across business segments H1 2020 Year-on-year Sales Revenue Change by Business Segment | Business Segment | Year-on-year Growth Rate | | :--- | :--- | | Compound Food Additives | +3.86% | | Edible Probiotic Products | +83.62% | | Animal and Plant Micro-ecological Preparations | -21.09% | - Benefiting from the increased proportion of high-margin edible probiotic products, the company's overall gross profit margin increased by **0.88%** year-on-year, further optimizing its business structure[44](index=44&type=chunk) [Analysis of Main Business](index=12&type=section&id=II.%20Analysis%20of%20Main%20Business) Key financial metrics saw significant year-on-year changes, including a 227.08% decrease in financial expenses and a 69.40% increase in R&D investment Year-on-year Changes in Key Financial Data | Item | Current Reporting Period (Million Yuan) | Prior Year Period (Million Yuan) | Year-on-year Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Financial Expenses | -0.17 | 0.13 | -227.08% | Primarily due to increased interest income | | R&D Investment | 7.78 | 4.59 | 69.40% | Primarily due to increased investment in R&D projects during the reporting period | | Net Cash Flow from Operating Activities | 25.88 | 44.31 | -41.58% | Major client Mengniu Dairy settled with bank acceptance bills | | Net Cash Flow from Investing Activities | -15.66 | -23.97 | -34.68% | Reduced payments for engineering projects year-on-year | | Non-operating Expenses | 3.25 | 0.00 | 179,291.58% | Due to COVID-19 pandemic donations and disposal of fixed assets | [Analysis of Assets and Liabilities](index=14&type=section&id=IV.%20Analysis%20of%20Assets%20and%20Liabilities) The asset structure shifted, with fixed assets increasing to 13.01% of total assets and accounts receivable decreasing to 10.07%, reflecting asset transfers and settlement changes Significant Changes in Asset Composition | Item | Amount at End of Current Reporting Period (Million Yuan) | Proportion of Total Assets | Amount at End of Prior Year Period (Million Yuan) | Proportion of Total Assets | Change in Proportion | | :--- | :--- | :--- | :--- | :--- | :--- | | Accounts Receivable | 49.49 | 10.07% | 99.46 | 24.20% | -14.13% | | Fixed Assets | 63.97 | 13.01% | 21.45 | 5.22% | 7.79% | | Construction in Progress | 124.23 | 25.27% | 150.66 | 36.64% | -11.37% | [Analysis of Investment Status](index=14&type=section&id=V.%20Analysis%20of%20Investment%20Status) The company had no major equity or non-equity investments or use of raised funds, but invested 79 million yuan of idle self-owned funds in bank wealth management products - The company invested **79 million yuan** of idle self-owned funds in bank wealth management products[56](index=56&type=chunk) [Risks Faced by the Company and Countermeasures](index=16&type=section&id=IX.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces risks from market competition, high customer concentration, potential technology leakage, and increased depreciation post-IPO, with mitigation strategies in place - Key risk points: - **Market Competition**: Faces competition from international giants like Danisco and DuPont[61](index=61&type=chunk) - **Customer Concentration**: Operating revenue primarily derived from a few large dairy enterprises such as Mengniu and Guangming[63](index=63&type=chunk) - **Technology Leakage**: Risks of core strain and product formula leakage exist[64](index=64&type=chunk) - **Increased Depreciation**: IPO projects will lead to a significant increase in fixed assets and depreciation expenses, potentially impacting short-term profits[64](index=64&type=chunk) [Significant Events](index=18&type=section&id=Section%20V%20Significant%20Events) [Summary of Significant Events](index=18&type=section&id=Summary%20of%20Significant%20Events) The company held its 2019 annual general meeting, plans no semi-annual profit distribution, and had no major litigation, penalties, media queries, or related party transactions - The company plans no cash dividends, bonus shares, or capital increase from capital reserves for the semi-annual period[71](index=71&type=chunk) - During the reporting period, the company had no major litigation, arbitration, media queries, penalties and rectifications, or significant related party transactions[76](index=76&type=chunk)[77](index=77&type=chunk)[79](index=79&type=chunk) [Share Changes and Shareholder Information](index=22&type=section&id=Section%20VI%20Share%20Changes%20and%20Shareholder%20Information) [Share Change Status](index=22&type=section&id=I.%20Share%20Change%20Status) As of June 30, 2020, total share capital was 61,887,692 shares, all restricted; post-reporting period, the company listed on July 27, 2020, increasing total shares to 82,517,692 - The share capital remained unchanged during the reporting period, but the company completed its initial public offering and listing on the ChiNext board on July 27, 2020, increasing its total share capital to **82,517,692 shares**[97](index=97&type=chunk) [Number of Shareholders and Shareholding Status](index=23&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Status) As of the reporting period end, the company had 11 common shareholders, with Sun Tiansong holding 40.32% and Beijing Kerongda Investment Partnership holding 16.13% Top Five Shareholders' Shareholding Status (as of June 30, 2020) | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares | | :--- | :--- | :--- | :--- | | Sun Tiansong | Domestic Natural Person | 40.32% | 24,954,801 | | Beijing Kerongda Investment Partnership (Limited Partnership) | Domestic Non-state-owned Legal Person | 16.13% | 9,985,506 | | Liu Xiaojun | Domestic Natural Person | 8.77% | 5,430,301 | | Zhang Liebing | Domestic Natural Person | 8.54% | 5,287,801 | | Qiao Xiangqian | Domestic Natural Person | 7.11% | 4,403,000 | [Information on Preferred Shares](index=25&type=section&id=Section%20VII%20Information%20on%20Preferred%20Shares) [7.1 Preferred Shares](index=25&type=section&id=7.1%20Preferred%20Shares) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[105](index=105&type=chunk) [Information on Convertible Corporate Bonds](index=26&type=section&id=Section%20VIII%20Information%20on%20Convertible%20Corporate%20Bonds) [8.1 Convertible Corporate Bonds](index=26&type=section&id=8.1%20Convertible%20Corporate%20Bonds) The company had no convertible corporate bonds during the reporting period - The company had no convertible corporate bonds during the reporting period[108](index=108&type=chunk) [Information on Directors, Supervisors, and Senior Management](index=27&type=section&id=Section%20IX%20Information%20on%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) [9.1 Changes in Directors, Supervisors, and Senior Management](index=27&type=section&id=9.1%20Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) There were no changes in the shareholdings or composition of the company's directors, supervisors, and senior management during the reporting period - The company's directors, supervisors, and senior management had no changes in shareholdings or personnel during the reporting period[110](index=110&type=chunk)[111](index=111&type=chunk) [Information on Corporate Bonds](index=28&type=section&id=Section%20X%20Information%20on%20Corporate%20Bonds) [10.1 Corporate Bonds](index=28&type=section&id=10.1%20Corporate%20Bonds) The company has no publicly issued and listed corporate bonds that are unexpired or fully redeemed as of the report approval date - The company has no unexpired or fully unredeemed corporate bonds[114](index=114&type=chunk) [Financial Report](index=29&type=section&id=Section%20XI%20Financial%20Report) [Financial Statements](index=29&type=section&id=II.%20Financial%20Statements) This section presents the consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity as of June 30, 2020 [1. Consolidated Balance Sheet](index=29&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of June 30, 2020, total assets were 491.60 million yuan, total liabilities were 53.19 million yuan, and total owners' equity attributable to the parent company was 438.41 million yuan Consolidated Balance Sheet Key Items (June 30, 2020) | Item | Amount (Million Yuan) | | :--- | :--- | | Total Assets | 491.60 | | Total Liabilities | 53.19 | | Total Owners' Equity Attributable to Parent Company | 438.41 | | Total Liabilities and Owners' Equity | 491.60 | [3. Consolidated Income Statement](index=35&type=section&id=3.%20Consolidated%20Income%20Statement) In H1 2020, total operating revenue was 140.15 million yuan, total operating costs were 94.08 million yuan, and net profit was 38.58 million yuan Consolidated Income Statement Key Items (H1 2020) | Item | Amount (Million Yuan) | | :--- | :--- | | I. Total Operating Revenue | 140.15 | | II. Total Operating Costs | 94.08 | | III. Operating Profit | 49.27 | | IV. Total Profit | 46.03 | | V. Net Profit | 38.58 | [5. Consolidated Cash Flow Statement](index=39&type=section&id=5.%20Consolidated%20Cash%20Flow%20Statement) In H1 2020, net cash flow from operating activities was 25.88 million yuan, net cash flow from investing activities was -15.66 million yuan, and cash and cash equivalents at period-end were 110.33 million yuan Consolidated Cash Flow Statement Key Items (H1 2020) | Item | Amount (Million Yuan) | | :--- | :--- | | Net Cash Flow from Operating Activities | 25.88 | | Net Cash Flow from Investing Activities | -15.66 | | Net Cash Flow from Financing Activities | 0.00 | | Net Increase in Cash and Cash Equivalents | 10.23 | | Cash and Cash Equivalents at Period-end | 110.33 | [Notes to Consolidated Financial Statement Items](index=77&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed explanations for significant items in the consolidated financial statements, including their composition, changes, and accounting policies [61. Operating Revenue and Operating Costs](index=108&type=section&id=61.%20Operating%20Revenue%20and%20Operating%20Costs) In H1 2020, main business revenue was 140.15 million yuan, with compound food additives contributing 115.61 million yuan (approx. 82.5% of total revenue) Main Business Revenue Composition (H1 2020) | Product Category | Revenue (Million Yuan) | | :--- | :--- | | Compound Food Additives | 115.61 | | Edible Probiotic Products | 12.63 | | Animal and Plant Micro-ecological Preparations | 10.55 | | Other | 1.35 | | **Total** | **140.15** | [Supplementary Information](index=137&type=section&id=XVIII.%20Supplementary%20Information) This section provides supplementary financial information, including a detailed statement of non-recurring gains and losses, return on net assets, and earnings per share Return on Net Assets and Earnings Per Share (H1 2020) | Profit for the Reporting Period | Weighted Average Return on Net Assets | Basic EPS (yuan/share) | Diluted EPS (yuan/share) | | :--- | :--- | :--- | :--- | | Net profit attributable to common shareholders of the company | 9.21% | 0.62 | 0.62 | | Net profit attributable to common shareholders of the company after deducting non-recurring gains and losses | 9.04% | 0.61 | 0.61 | [Catalogue of Reference Documents](index=139&type=section&id=Section%20XII%20Catalogue%20of%20Reference%20Documents) [12.1 Reference Documents](index=139&type=section&id=12.1%20Reference%20Documents) Reference documents include the semi-annual report signed by the legal representative and the financial report signed and sealed by relevant financial officers - Reference documents include: - The semi-annual report text bearing the signature of the legal representative - The financial report text bearing the signatures and seals of the person in charge of the entity, the person in charge of accounting work, and the head of the accounting department - Other relevant materials[608](index=608&type=chunk)